The article in the October 2006 issue of the ARCHIVES by ElHassan and colleagues1 concludes that respiratory syncytial virus (RSV) prophylaxis with palivizumab is not cost-effective, and therefore its use should be restricted. While this study includes the effects of asthma sequelae from RSV infection, readers need to appreciate that 2 key assumptions in the paper are controversial and strongly influence the results.
Mahadevia PJ, Malinoski FJ. Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis With Palivizumab. Arch Pediatr Adolesc Med. 2007;161(5):519–520. doi:10.1001/archpedi.161.5.519